The relationship between plasma favipiravir concentrations and clinical outcomes in COVID-19.

The relationship between plasma favipiravir concentrations and clinical outcomes in COVID-19.

Publication date: Jul 01, 2026

Favipiravir has shown efficacy against SARS-CoV-2 in patients

Open Access PDF

Concepts Keywords
Clinical
Concentrations
Cov
Covid
Drugs
Efficacy
Erj
Favipiravir
Open
Outcomes
Plasma
Relationship
Res
Sars
Shown

Semantics

Type Source Name
drug DRUGBANK Favipiravir
disease MESH COVID-19
drug DRUGBANK Diflunisal
disease MESH NHS
drug DRUGBANK Ribostamycin

Original Article

(Visited 5 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *